摘要
由受体的过度表达或激活突变导致的表皮生长因子受体(EGFR)信号失调与肿瘤细胞的增殖,转移和生存相关。现已开发的EGFR已成为非–小细胞肺癌(NSCLC)的一个重要的治疗靶点,或作为非–小细胞肺癌(NSCLC)治疗的几个EGFR靶向药物,如酪氨酸激酶抑制剂(TKIs)和单克隆抗体(mAbs)。EGFR-TKIs吉非替尼 , 厄洛 替 尼 的 , 和 阿法替尼已经批准 用于 治疗 NSCLC晚期 ,这些药物的敏感性已被证明与表皮生长因子受体突变相关。各种单克隆抗体对表皮生长因子受体的临床前和临床研究中也进行了评价。特别是,III期临床试验结果显示,在化疗初治NSCLC晚期患者体内添加抗EGFR单抗西妥昔单抗或该药物与铂结合,临床显示对治疗非常有利。临床显著生存益处的抗EGFR单克隆抗体西妥昔单抗或试验一种铂化疗的晚期非小细胞肺癌患者钠ïVE添加。本文总结表皮生长因子受体靶向的单克隆抗体在治疗非小细胞肺癌过程中完成的和正在进行的临床试验结果。
关键词: 抗体,西妥昔单抗,表皮生长因子受体(EGFR),necitumumab,非小细胞肺癌,尼妥珠单抗,帕尼单抗。
图形摘要
Current Cancer Drug Targets
Title:Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Volume: 15 Issue: 9
Author(s): Masayuki Takeda and Kazuhiko Nakagawa
Affiliation:
关键词: 抗体,西妥昔单抗,表皮生长因子受体(EGFR),necitumumab,非小细胞肺癌,尼妥珠单抗,帕尼单抗。
摘要: Dysregulation of epidermal growth factor receptor (EGFR) signaling due to receptor overexpression or activating mutation is associated with cancer cell proliferation, metastasis, and survival. EGFR has become an important therapeutic target for non–small cell lung cancer (NSCLC), and several EGFR-targeted agents, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), have been developed. The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. Various mAbs to EGFR have also been evaluated in preclinical and clinical studies. In particular, phase III trials have shown a clinically significant survival benefit for addition of the anti-EGFR mAbs cetuximab or necitumumab to a platinum doublet in chemotherapy-naïve patients with advanced NSCLC. We here summarize the results of completed and ongoing clinical trials of EGFR-targeted mAbs for the treatment of NSCLC.
Export Options
About this article
Cite this article as:
Masayuki Takeda and Kazuhiko Nakagawa , Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer, Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/156800961509151110143001
DOI https://dx.doi.org/10.2174/156800961509151110143001 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Editorial: Smart Drug Delivery Systems (Part 1)
Current Drug Targets The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Anticancer Agents Derived from Natural Cinnamic Acids
Anti-Cancer Agents in Medicinal Chemistry Perspectives/Opinion: ADVANCED MEDICAL IMAGING IN THE ERA OF PERSONALIZED OR PRECISION MEDICINE
Current Medical Imaging Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Recent Progress in the Syntheses and Biological Evaluation of Boronated Porphyrins for Boron Neutron-Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry